Criteria for treatment-resistant epilepsy: The neuro-pediatrician's position;Critères de pharmaco-résistance d'une épilepsie: Les critères du neuropédiatre

Revue Neurologique

Volumn 160, Issue 5 SUPPL., 2004, Pages

  Raffo, E ^a  

^a HÔPITAL D ENFANTS   (France)

Author keywords

Childhood; Treatment resistant epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN;

ADOLESCENT; ANTICONVULSANT THERAPY; ANTIEPILEPTIC DRUG RESISTANCE; BRAIN MALFORMATION; BRAIN TUMOR; CHILD; CHILDHOOD DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DRUG RESISTANT EPILEPSY; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPTOGENESIS; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; INFANT; KETOGENIC DIET; MEDICAL SPECIALIST; NEUROSURGERY; NEWBORN; PEDIATRICIAN; PROGNOSIS; RISK FACTOR; SYNDROME DELINEATION;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; EXPERT TESTIMONY; HUMANS; INFANT; NEUROLOGY; PEDIATRICS; RISK FACTORS; SYNDROME;

EID: 4544287028     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. AICARDI J, OHTAHARA S (2002). Severe neonatal epilepsies with suppression-bursts pattern. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, Epileptic syndromes in infancy, childhood and adolescence. 33-44. John Libbey. London.
2. APPLETON R, FICHTNER K, LAMOREAUX L, et al. (1999). Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia 40(8): 1147-54.
3. ARONICA E, GORTER JA, JANSEN GH, et al. (2003). Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 118: 417-429.
4. ARROYO S, BRODIE MJ, AVANZINI G, et al. (2002). Is refractory epilepsy preventable? Epilepsia 43(4): 437-444.
5. BATTAGLIA D, DRAVET C, GÉLISSE P, et al. (1998). Pronostic des épilepsies partielle non idiopathiques chez l'enfant de moins de six ans. Bureau M, Kahane P, Munari C, Epilepsies partielles graves pharmaco- résistantes de l'enfant: stratégies diagnostiques et traitements chirurgicaux. John Libbey, Eurotext. Paris.
6. BERG AT, SHINNAR S, LEVY SR, et al. (2001). Early development of intractable epilepsy in children. Neurology 56: 1445-1452.
7. BUREAU M, MATON B (1998). Valeur de l'EEG dans le pronostic précoce des épilepsies partielles non idiopathiques de l'enfant. Bureau M, Kahane P, Munari C, Epilepsies partielles graves pharmaco- résistantes de l'enfant: stratégies diagnostiques et traitements chirurgicaux., 67-78. John Libbey, Eurotext. Paris.
8. CAMFIELD P, CAMFIELD C (1996). Antiepileptic drug therapy: when is epilepsy truly intractable? Epilepsia 37: S60-5
9. CENDES F, KAHANE P, BRODIE MJ, et al. (2002). The mesio-temporal lobe epilepsy syndrome. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, Epileptic syndromes in infancy, childhood and adolescence.
10. CHAPELL R, RESTON J, SNYDER D (2003). Management of Treatment-Resistant Epilepsy. Evidence Report/Technology Assessment No. 77. (Prepared by the ECRI Evidence-based Practice Center under Contract No 290-97-0020.), AHRQ Publication No. 03-0028 Rockville, MD: Agency for Healthcare research and Quality.
11. COMMISSION ON CLASSIFICATION AND TERMINOLOGY OF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY (1989). Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30(4): 389-99.
12. DRAVET C, BUREAU M, OGUNI H, et al. (2002). Severe myoclonic epilepsy in infancy (Dravet syndrome). Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, Epileptic syndromes in infancy, childhood and adolescence. 81-104. John Libbey. London.
13. DUCHOWNY M, PELLOCK JM, GRAF WD, et al. (1999). A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 53(8): 1724-31.
14. DULAC O (1998). Chirurgie de l'épilepsie de l'enfant et "plasticité" cérébrale. Bureau M, Kahane P, Munari C, Epilepsies partielles graves pharmaco-résistantes de l'enfant: stratégies diagnostiques et traitements chirurgicaux. 15-21. John Libbey, Eurotext. Paris.
15. DULAC O (2002). Migrating partial seizures in infancy. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, Epileptic syndromes in infancy, childhood and adolescence. 65-68. John Libbey. London.
16. DULAC O, GUERRINI R (2001). Seizure types and syndromes: lumping or splitting. Epilepsy Research 45: 37-40.
17. ELTERMAN RD, GLAUSER TA, WYLLIE E, et al. (1999). A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 52(7): 1338-44.
18. FREEMAN JM, VINING EP, PILLAS DJ, et al. (1998). The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics 102(6): 1358-63.
19. FRENCH J, SMITH M, FAUGHT E, et al. (1999). Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 52(8): 1540-5.
20. GLAUSER TA, NIGRO M, SACHDEO R, et al. (2000). Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology 54(12): 2237-44.
21. GUERRINI R, HOLTHAUSEN H, PARMEGGIANI L, et al. (2002). Epilepsy and malformations of the cerebral cortex. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, Epileptic syndromes in infancy, childhood and adolescence. 457-480. John Libbey. London.
22. HAUSER WA (1992). The natural history of drug resistant epilepsy: epidemiologic considerations. Epilepsy Research Suppl. 5: 25-28.
23. JALLON P (1998). Apport de l'épidémiologie dans l'évaluation de la gravité des épilepsies de l'enfant. Bureau M, Kahane P, Munari C, Epilepsies partielles graves pharmaco- résistantes de l'enfant: stratégies diagnostiques et traitements chirurgicaux, 49-54. John Libbey, Eurotext. Paris.
24. KAHANE P, BUREAU M, REVOL M, et al. (2002). Non idiopathic partial epilepsies of childhood. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, Epileptic syndromes in infancy, childhood and adolescence. 229-246. John Libbey. London.
25. KAMINSKA A (2001). New antiepileptic drugs in childhood epilepsies: indications and limits. Epileptic disorders 3(4-S2): 37-46.
26. KWAN P, BRODIE MJ (2000). Early identification of refractory epilepsy. New England Journal of Medicine 342: 314-319.
27. KWAN P, BRODIE MJ (2001). Effectiveness of first antiepileptic drug. Epilepsia 42: 1255-60.
28. LORTIE A, PLOUIN P, CHIRON C, et al. (2002). Chracteristics of epilepsy in focal cortical dysplasia in infancy. Epilepsy Research 51: 133-145.
29. LOSCHER W, POTSCHKA H (2002). Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp ther 307(1): 7-14.
30. MIZRAHI EM, WATANABE K (2002). Symptomatic neonatal seizures. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, Epileptic syndromes in infancy, childhood and adolescence. 15-32. John Libbey. London.
31. PERUCCA E (1996). Pharmacoresistance. Electroencephalogr. Clin. Neurophysiol. 99(4): 388.
32. PERUCCA E, GRAM L, AVANZINI G, et al. (1998). Antiepileptic drugs as a cause of worsening seizures. Epilepsia 39(1): 5-17.
33. PLOUIN P, ANDERSON VE (2002). Benign familial and non-familial neonatal seizures. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, WOLF P, Epileptic syndromes in infancy, childhood and adolescence. 3-14. John Libbey. London.
34. PLOUIN P, RAFFO E, DE OLIVEIRA T (2003). Prognosis of neonatal seizures. Jallon P, Prognosis of Epilepsies. 199-209. John Libbey Eurotext. Paris.
35. REGESTA G, TANGANELLI P (1999). Clinical aspects and biological bases of drug-resistant epelepsies. Epilepsy Research 34: 109-122.
36. REMY S, GABRIEL S, URBAN BW, et al. (2003). A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 53: 469-479.
37. ROGER J, DRAVET C, MENENDEZ P, et al. (1981). [The partial epilepsies in childhood-evolution and prognosis factors (author's transl)]. Rev Electroencephalogr Neurophysiol Clin 11(3-4): 431-7.
38. SIDDIQUI A, REINHOLD K, WEALE ME, et al. (2003). Association of multidrug resistance in epilepsy with a ploymorphism in the drug-transporter gene ABCB1. New England Journal of Medicine 348: 1442-1448.
39. SIGLER M, STRASSBURG HM, BOENIGK HE (2001). Effective and safe but forgotten: methsuximide in intractable epilepsies in childhood. Seizure 10(2): 120-4.
40. VIGEVANO F, BUREAU M (2002). Idiopathic and/or benign localization-related epilepsies in infants and young children. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, Epileptic syndromes in infancy, childhood and adolescence. 161-177. John Libbey. London.
41. VINING EP, FREEMAN JM, BALLABAN-GIL K, et al. (1998). A multicenter study of the efficacy of the ketogenic diet. Arch Neurol 55(11): 1433-7.
42. WATANABE K, OKUMURA A, ASO K (2002). Non-idiopathic localization-related epilepsies in infants and young children. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, Epileptic syndromes in infancy, childhood and adolescence. 161-177. John Libbey. London.
43. WESTVELD M, SASS KJ, CHELUNE GJ, et al. (2000). Temporal lobectomy in children: cognitive outcome. J Neurosurg 92(1): 24-30.